公开(公告)号：US20200283479A1

公开(公告)日：2020-09-10

申请号：US16881198

申请日：2020-05-22

申请人： Ironwood Pharmaceuticals, Inc.

发明人： Angelika Fretzen ,  Hong Zhao ,  Marco Kessler

IPC分类号： C07K7/08 ,  A61K38/10 ,  A61K45/06 ,  A61K38/08 ,  C07K7/06

摘要： The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

公开(公告)号：US20190029967A1

公开(公告)日：2019-01-31

申请号：US16129951

申请日：2018-09-13

申请人： Ironwood Pharmaceuticals, Inc. ,  Forest Laboratories Holdings Limited

发明人： Angelika Fretzen ,  Steven Witowski ,  Alfredo Grossi ,  Hong Zhao ,  Mahendra Dedhiya ,  Yun Mo

IPC分类号： A61K9/50 ,  G01N30/02 ,  A61K9/16 ,  B65D81/26 ,  A61K47/36 ,  A61K47/18 ,  A61K47/02 ,  A61K38/12 ,  A61K38/10 ,  A61K9/48 ,  A61K9/20

摘要： Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

公开(公告)号：US20150132375A1

公开(公告)日：2015-05-14

申请号：US14597599

申请日：2015-01-15

申请人： Ironwood Pharmaceuticals, Inc. ,  Forest Laboratories Holdings Limited

发明人： Angelika Fretzen ,  Steven Witowski ,  Alfredo Grossi ,  Hong Zhao ,  Mahendra Dedhiya ,  Yun Mo

IPC分类号： A61K9/50 ,  A61K47/02 ,  B65D81/26 ,  A61K47/36 ,  G01N30/02 ,  A61K38/12 ,  A61K47/18

CPC分类号： A61K9/50 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5078 ,  A61K38/10 ,  A61K38/12 ,  A61K47/02 ,  A61K47/183 ,  A61K47/36 ,  B65D81/26 ,  G01N30/02 ,  G01N2030/027

摘要： Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

摘要翻译： 适用于口服给药的利那洛肽的固体稳定制剂在本文中描述为制备这些制剂的方法。 本文描述的制剂含有由氨基酸序列Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr（“linaclotide”; SEQ ID NO：1）或其药学上可接受的盐组成的多肽。 本文所述的利那洛肽制剂是稳定的并且具有用于制造，储存和分配药物的足够的保质期。

公开(公告)号：US20140287034A1

公开(公告)日：2014-09-25

申请号：US14286062

申请日：2014-05-23

申请人： Ironwood Pharmaceuticals, Inc. ,  Forest Laboratories Holdings Limited

发明人： Angelika Fretzen ,  Steven Witowski ,  Alfredo Grossi ,  Hong Zhao ,  Mahendra Dedhiya ,  Yun Mo

IPC分类号： A61K9/50 ,  G01N30/02 ,  A61K47/18 ,  A61K47/36 ,  A61K38/12 ,  A61K47/02

CPC分类号： A61K9/50 ,  A61K9/1611 ,  A61K9/1617 ,  A61K9/1623 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5078 ,  A61K38/10 ,  A61K38/12 ,  A61K47/02 ,  A61K47/183 ,  A61K47/36 ,  B65D81/26 ,  G01N30/02 ,  G01N2030/027

摘要： Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

摘要翻译： 适用于口服给药的利那洛肽的固体稳定制剂在本文中描述为制备这些制剂的方法。 本文描述的制剂含有由氨基酸序列Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr（“linaclotide”; SEQ ID NO：1）或其药学上可接受的盐组成的多肽。 本文所述的利那洛肽制剂是稳定的并且具有用于制造，储存和分配药物的足够的保质期。

公开(公告)号：US20220125734A1

公开(公告)日：2022-04-28

申请号：US17570713

申请日：2022-01-07

申请人： Ironwood Pharmaceuticals, Inc. ,  Forest Laboratories Holdings Limited

发明人： Angelika Fretzen ,  Steven Witowski ,  Alfredo Grossi ,  Hong Zhao ,  Mahendra Dedhiya ,  Yun Mo

IPC分类号： A61K9/50 ,  A61K9/16 ,  A61K9/20 ,  A61K9/48 ,  A61K38/10 ,  A61J3/00 ,  A61K38/12 ,  A61K47/02 ,  A61K47/18 ,  A61K47/36 ,  B65D81/26 ,  G01N30/02

摘要： Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr (“linaclotide”; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

公开(公告)号：US20210388026A1

公开(公告)日：2021-12-16

申请号：US17459451

申请日：2021-08-27

申请人： Ironwood Pharmaceuticals, Inc.

发明人： Angelika Fretzen ,  Hong Zhao ,  Marco Kessler

IPC分类号： C07K7/08 ,  A61K38/10 ,  A61K45/06 ,  A61K38/08 ,  C07K7/06

摘要： The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

公开(公告)号：US20210032292A1

公开(公告)日：2021-02-04

申请号：US17066802

申请日：2020-10-09

申请人： Ironwood Pharmaceuticals, Inc.

发明人： Marco Kessler ,  Angelika Fretzen ,  Hong Zhao ,  Robert Solinga ,  Vladimir Volchenok

IPC分类号： C07K7/08 ,  C11D3/34 ,  C07K7/54 ,  C07K5/02 ,  A61K38/10 ,  A61K38/12 ,  A61K45/06

摘要： The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

公开(公告)号：US20230272007A1

公开(公告)日：2023-08-31

申请号：US18143892

申请日：2023-05-05

申请人： Ironwood Pharmaceuticals, Inc.

发明人： Marco Kessler ,  Angelika Fretzen ,  Hong Zhao ,  Robert Solinga ,  Vladimir Volchenok

IPC分类号： C07K7/08 ,  C11D3/34 ,  C07K7/54 ,  C07K5/02 ,  A61K38/10 ,  A61K38/12 ,  A61K45/06

CPC分类号： C07K7/08 ,  C11D3/3436 ,  C07K7/54 ,  C07K5/02 ,  A61K38/10 ,  A61K38/12 ,  A61K45/06 ,  G01N2800/065 ,  Y02A50/30

摘要： The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

公开(公告)号：US20220227812A1

公开(公告)日：2022-07-21

申请号：US17716560

申请日：2022-04-08

申请人： Ironwood Pharmaceuticals, Inc.

发明人： Angelika Fretzen ,  Hong Zhao ,  Marco Kessler

IPC分类号： C07K7/08 ,  A61K38/10 ,  A61K45/06 ,  A61K38/08 ,  C07K7/06

摘要： The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.

公开(公告)号：US20190062376A1

公开(公告)日：2019-02-28

申请号：US16171524

申请日：2018-10-26

申请人： Ironwood Pharmaceuticals, Inc.

发明人： Marco Kessler ,  Angelika Fretzen ,  Hong Zhao ,  Robert Solinga ,  Vladimir Volchenok

IPC分类号： C07K7/08 ,  C11D3/34 ,  C07K5/02 ,  C07K7/54 ,  A61K38/10 ,  A61K45/06 ,  A61K38/12

摘要： The present invention features peptides, compositions, and related methods for treating gastrointestinal disorders and conditions, including but not limited to, irritable bowel syndrome (IBS), gastrointestinal motility disorders, functional gastrointestinal disorders, gastroesophageal reflux disease (GERD), duodenogastric reflux, Crohn's disease, ulcerative colitis, inflammatory bowel disease, functional heartburn, dyspepsia, visceral pain, gastroparesis, chronic intestinal pseudo-obstruction (or colonic pseudo-obstruction), disorders and conditions associated with constipation, and other conditions and disorders are described herein. using peptides and other agents that activate the guanylate cyclase C (GC-C) receptor.